Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
1. A pharmaceutical formulation for the treatment of narcolepsy or a symptom thereof, comprising:
(a) an amount of gamma-hydroxybutyrate equivalent to from 3.0 g to 12.0 g of sodium oxybate;
(b) microcrystalline cellulose spheres;
(c) methacrylic acid and methyl methacrylate copolymer;
(d) methacrylic acid and ethyl acrylate copolymer,
(e) hydrogenated vegetable oil; and
(f) an acidifying agent,
wherein the weight ratio of the methacrylic acid and methyl methacrylate copolymer to the methacrylic acid and ethyl acrylate copolymer is about 2:1 (w/w), and
wherein the formulation is designed to be administered orally only once nightly.
2. The pharmaceutical formulation of claim 1 , wherein the acidifying agent is selected from the group consisting of malic acid, citric acid, tartaric acid, adipic acid, boric acid, maleic acid, phosphoric acid, ascorbic acid, oleic acid, capric acid, caprylic acid, and benzoic acid, and mixtures thereof.
3. The pharmaceutical formulation of claim 1 , wherein the acidifying agent is selected from the group consisting of malic acid, tartaric acid, and mixtures thereof.
4. The pharmaceutical formulation of claim 1 , wherein the acidifying agent comprises 1.2% to 15% (w/w) of the formulation.
5. The pharmaceutical formulation of claim 1 , wherein the acidifying agent comprises 1.2% to 10% (w/w) of the formulation.
6. The pharmaceutical formulation of claim 1 , wherein the acidifying agent comprises 1.2% to 5% (w/w) of the formulation.
7. The pharmaceutical formulation of claim 1 , wherein the acidifying agent comprises 1.6% to 3.2% (w/w) of the formulation.
8. The pharmaceutical formulation of claim 1 , wherein the acidifying agent comprises about 1.6% (w/w) of the formulation.
9. A pharmaceutical formulation for the treatment of narcolepsy or a symptom thereof, comprising:
(a) an amount of gamma-hydroxybutyrate equivalent to 3.0 g, 4.5 g, 6.0 g, 7.5 g, 9.0 g, 10.5 g, or 12.0 g of sodium oxybate;
(b) microcrystalline cellulose spheres;
(c) methacrylic acid and methyl methacrylate copolymer;
(d) methacrylic acid and ethyl acrylate copolymer,
(e) hydrogenated vegetable oil; and
(f) malic acid,
wherein the weight ratio of the methacrylic acid and methyl methacrylate copolymer to the methacrylic acid and ethyl acrylate copolymer is about 2:1 (w/w), and
wherein the formulation is designed to be administered orally only once nightly.
10. A pharmaceutical formulation for the treatment of narcolepsy or a symptom thereof, comprising:
an immediate release portion comprising gamma-hydroxybutyrate;
a delayed release portion comprising gamma-hydroxybutyrate and a coating, the coating comprising:
about 4.48% (w/w) methacrylic acid and methyl methacrylate copolymer;
about 2.23% (w/w) methacrylic acid and ethyl acrylate copolymer;
about 10.07% (w/w) hydrogenated vegetable oil; and
an acidifying agent.
11. A pharmaceutical formulation for the treatment of narcolepsy or a symptom thereof, comprising:
an immediate release portion comprising gamma-hydroxybutyrate; and
a delayed release portion comprising gamma-hydroxybutyrate and a coating, the coating comprising:
about 0.318 g methacrylic acid and methyl methacrylate copolymer;
about 0.159 g methacrylic acid and ethyl acrylate copolymer; and
about 0.716 g hydrogenated vegetable oil; and
malic acid, wherein the amount of gamma-hydroxybutyrate in the formulation is equivalent to 3.0 g, 4.5 g, 6.0 g, 7.5 g, 9.0 g, 10.5 g, or 12.0 g of sodium oxybate.